Adverse event profiles of selpercatinib: a real-world pharmacovigilance analysis based on FAERS database DOI Creative Commons

Jiancheng Qian,

Shuohan Zhang,

Cheng Jiang

и другие.

BMC Cancer, Год журнала: 2024, Номер 24(1)

Опубликована: Дек. 3, 2024

Selpercatinib, a highly selective tyrosine kinase inhibitor, has emerged as an excellent treatment option for patients with rearranged during transfection-altered cancer. However, there is limited comprehensive safety information available selpercatinib through large-scale post-marketing monitoring. This study conducted analysis of selpercatinib-related adverse events (AEs) using the FDA Adverse Event Reporting System database. Four disproportionality methods were employed to identify potential AEs associated selpercatinib. Specifically, this investigated differences in respect reporter continent, indication, sex, age, weight, dose, frequency, and onset time. A total 464 reports 1,007 identified. Three new significant discovered, including dysphagia, pericardial effusion, hemiparesis. Notably, Asia reported hepatic function abnormal more frequently, especially patient administered doses exceeding 160 mg. Furthermore, hypersensitivity was frequently by individuals weighing less than 50 kg. It paramount stay vigilant concerning emergence three newly identified AEs. Significant found time, which deserved clinical attention. These findings contribute broader understanding AE profiles • single Hypersensitivity

Язык: Английский

Ginsenoside Rh2(S) maintains cytoskeleton homeostasis and inhibits pyroptosis to resist cisplatin-induced cardiotoxicity through FGFR1/HRAS axis DOI

Hongbo Teng,

Shuai Huang,

Xialin Sun

и другие.

Phytomedicine, Год журнала: 2025, Номер 138, С. 156425 - 156425

Опубликована: Янв. 24, 2025

Язык: Английский

Процитировано

1
Network pharmacology to unveil the blood components and mechanisms of Tongmai Yangxin Pills in treating elderly coronary heart disease DOI Creative Commons
Y. Zhang, Chaohui Li,

Yi-Zhi Yan

и другие.

Frontiers in Cardiovascular Medicine, Год журнала: 2025, Номер 12

Опубликована: Фев. 13, 2025

Background Tongmai Yangxin Pills (TMYXP) is a well-known traditional Chinese medicine compound to treat coronary heart disease (CHD). Aging key immutable independent risk factor for CHD. Currently, there are few gene expression profiles of patients treated with (TCM) or TCM compound. However, the chemical composition and underlying mechanisms TMYXP against elderly CHD need be elucidated. Objective Exploring mechanism in treating based on human profiles, find pharmacodynamic ingredients plasma pharmacochemistry network pharmacology. Methods A strength this study use pharmacology analysis before after treatment. This focused peripheral blood mononuclear cell samples from 6 over 60 years old (GSE142008). total 40 components identified by UPLC/Q-TOF-MS method SD rats. Then, we collected literature-validated component targets further analysis. Results All exhibited non-toxic properties. By retrieving validated components's targets, 15 correspond 4,789 targets. Genistein, emodin, isoliquiritigenin, glycyrrhizic acid, gallic verbascoside, calycosin, rhein, formononetin ephedrine were most potential anti-CHD TMYXP. The above 10 mainly regulate hub genes CASP3, TGFB1, PTGS2, CXCL8, FAS JAK2 , mediating multiple exerts effects TNF signaling pathway, PI3K-Akt p53 MAPK lipid atherosclerosis, NOD-like receptor diabetic cardiomyopathy cytokine-cytokine interaction. We used molecular docking technology verify direct interaction its target Conclusion builds bridge connecting confirmed clinical efficacy, identifies series lead compounds, analyzes their possible research strategy has promote modernization transformation drug development.

Язык: Английский

Процитировано

1
Functional characterization and protein engineering of glycosyltransferase for 2”-O-xylosylation of ginsenoside Rg3 DOI
Zhen Guo, Pengfei Li,

Chaokang Huang

и другие.

International Journal of Biological Macromolecules, Год журнала: 2025, Номер unknown, С. 142539 - 142539

Опубликована: Март 1, 2025

Язык: Английский

Процитировано

0
Rapid and accurate identification of Panax ginseng origins based on data fusion of near-infrared and laser-induced breakdown spectroscopy DOI

Jiacong Ping,

Nan Hao,

Xuting Guo

и другие.

Food Research International, Год журнала: 2025, Номер 204, С. 115925 - 115925

Опубликована: Фев. 7, 2025

Язык: Английский

Процитировано

0
Adverse event profiles of selpercatinib: a real-world pharmacovigilance analysis based on FAERS database DOI Creative Commons

Jiancheng Qian,

Shuohan Zhang,

Cheng Jiang

и другие.

BMC Cancer, Год журнала: 2024, Номер 24(1)

Опубликована: Дек. 3, 2024

Selpercatinib, a highly selective tyrosine kinase inhibitor, has emerged as an excellent treatment option for patients with rearranged during transfection-altered cancer. However, there is limited comprehensive safety information available selpercatinib through large-scale post-marketing monitoring. This study conducted analysis of selpercatinib-related adverse events (AEs) using the FDA Adverse Event Reporting System database. Four disproportionality methods were employed to identify potential AEs associated selpercatinib. Specifically, this investigated differences in respect reporter continent, indication, sex, age, weight, dose, frequency, and onset time. A total 464 reports 1,007 identified. Three new significant discovered, including dysphagia, pericardial effusion, hemiparesis. Notably, Asia reported hepatic function abnormal more frequently, especially patient administered doses exceeding 160 mg. Furthermore, hypersensitivity was frequently by individuals weighing less than 50 kg. It paramount stay vigilant concerning emergence three newly identified AEs. Significant found time, which deserved clinical attention. These findings contribute broader understanding AE profiles • single Hypersensitivity

Язык: Английский

Процитировано

2